General characteristics and therapeutic options in lung cancer in Turkey
Küçük Resim Yok
Tarih
2015
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
European Respiratory Soc Journals Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
ASPECT study, a prospective multicenter study conducted in Turkey with the participation of 26 centers, including all patients with lung cancer, who agreed to participate in the study, were re-evaluated in terms of demographic characteristics of patients (pts), disease characteristics, and the treatment options in lung cancer. Among 1245 cases (88.7% man) included, %83.4 had advanced stage (stage 3-4) lung cancer. Histopathologic types were squamous cell in 39.3%, adenocancer in 29.6%, SCLC in 19.0%, NSCLC in 10.2% and others. Of the pts, 45.5% had a comorbid disease, 49.3% had weight loss (at least 5% of body weight), and 31.6% had a history of cancer in family. PET-CT was used in 83.3% of the pts for diagnosis of staging. Metastasis was detected in 54.2% of pts (43.9% bone, 23.1% brain, %20.2% liver, 17.3% surrenal metastasis). Treatment options were chemotherapy in 45.9%, chemo-radiotherapy in 28.2%, and surgery in 18.4% of the pts. Chemotherapy was mostly platin based doubles including etoposide (14.9%), paclitaxel (14.0%), gemcitabine (12.3%), docetaxol (4.3%), pemetrexed (2.2%), vinorelbin (4.9%), and others. The use of targeted therapies was detected in 1.1% of the pts. Palliative radiotherapy was given in 21.1% of the pts (8.5% brain, 7.2% bone, 6.7% thorax, and others). Interventional bronchoscopy or bronchial stenting was performed in 2.0% and pleurodesis in 1.8%. Of the pts, 10.5% reported the use of herbal medicine products. Most pts with lung cancer presented in advanced stages and only 18.4% had a chance for surgery. Conventional chemotherapy and radiotherapy was the most common therapeutic options but the use of targeted therapies and interventional procedures seems to be quite low.
Açıklama
Anahtar Kelimeler
Lung cancer / Oncology, Neoplastic Diseases, Mediastinal Tumour
Kaynak
European Respiratory Journal
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
46
